Merck & Co challenge to Vioxx securities lawsuit gets US high court hearing next week
This article was originally published in Scrip
Executive Summary
During oral arguments to the US Supreme Court on November 30th, Merck & Co will seek dismissal of a Vioxx securities fraud class action by arguing that plaintiffs should have known more than two years before filing suit in November 2003 that the company's "naproxen hypothesis" to explain away Vioxx's negative cardiovascular effects may have been incorrect.